An Intervention Study to Evaluate a Medication (MIJ821) Used to Treat Major Depressive Disorder
Official Title
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With IntentPurpose
The purpose of the study is to determine if the investigational study drug will rapidly reduce depression associated with thoughts of harming oneself when given in addition to standard antidepressant medication.
Your participation in this study will last for a minimum of 14 weeks and maximum of 58 weeks.
Could this study be right for you?
• Aged 18-65 years old
• Diagnosed with major depressive disorder (MDD) with a current major depressive episode
• Having current suicidal ideation with intent
• Already in the hospital or agree to be hospitalized voluntarily for the required period of time